Analytical framing of Amyloid beta monoclonal antibody trials in Alzheimer’s disease can obscure clinical effects

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract Cochrane Reviews are widely regarded as the gold standard for evidence synthesis, yet analytical framing influences interpretation. A recent Cochrane review of amyloid beta–targeting monoclonal antibodies pools mechanistically and biologically heterogenous...

CONNECT4 APOE: A randomized trial of telephone versus real‐time two‐way videoconference for disclosure of APOE genotype results in cognitively unimpaired adults

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract INTRODUCTION Data are needed to inform best practices for disclosing apolipoprotein E (APOE) results given increasing indications for testing. METHODS CONNECT4, a multi-center, randomized trial (NCT02978729) compared disclosure of APOE genotype by...

Alzheimer’s blood‐based biomarkers, incident dementia, and interactions with age, APOE status, and hormone therapy

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Abstract INTRODUCTION Cognitive impairment among older adults is often due to multiple pathologies and heterogenous risk factors. We assessed whether Alzheimer’s blood-based biomarkers (BBMs) were associated with incident mild cognitive impairment (MCI)/probable...

Superficial white matter and gray matter jointly support cognition among older adults in India

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

ABSTRACT INTRODUCTION The relationships between superficial white matter (SWM) and cognition, and its interaction with gray matter (GM), remain unclear in community-based populations. METHODS We analyzed data from 459 older adults in the Harmonized Diagnostic...

Alzheimer’s Association convenes public health leaders from state and local health departments to accelerate national dementia response

by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia

Alzheimer’s &Dementia, Volume 22, Issue 7, July 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | July 28, 2026 Neuro-Dementia Previous...

Standardizing care for agitation in Alzheimer’s disease, results from a randomized controlled trial of an integrated care pathway versus usual care – the StaN trial

by Clinical Neuropsychologist Online | Monday, July 27, 2026 | Dementia

Abstract BACKGROUND Adherence to treatment guidelines for agitation in dementia is suboptimal and inconsistent. We designed and evaluated an Integrated Care Pathway (ICP) for the management of agitation in dementia. METHODS This was a double-blind randomized...